Proteomics in prostate cancer biomarker discovery

References

• Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer101(10 Suppl.), 2371–2490 (2004).
   PubMed Web of Science ®Google Scholar
• Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front. Biosci.11, 1388–1413 (2006).
   PubMed Web of Science ®Google Scholar
• Crawford ED. Epidemiology of prostate cancer. Urology62(6 Suppl. 1), 3–12 (2003).
   PubMed Web of Science ®Google Scholar
• Bratt O. Hereditary prostate cancer: clinical aspects. J. Urol.168(3), 906–913 (2002).
   PubMed Web of Science ®Google Scholar
• Kehinde EO. The geography of prostate cancer and its treatment in Africa. Cancer Surv.23, 281–286 (1995).
   PubMedGoogle Scholar
• Heyns C, Lecuona A, Trollip G. Prostate cancer: prevalence and treatment in African men. J. Mens Health Gend.2(4), 400–405 (2005).
   Google Scholar
• Stanford JL, Stephenson RA, Coyle LM et al. Prostate cancer trends 1973–1995, SEER Program, National Cancer Institute. NIH Pub.93–3640 (1999).
   Google Scholar
• Gilbert SM, Benson MC, McKiernan JM. Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African–American population. Curr. Urol. Rep.3(3), 189–193 (2002).
   PubMedGoogle Scholar
• Gopalkrishnan RV, Kang D, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J. Cell. Physiol.189(3), 245–256 (2001).
   PubMedGoogle Scholar
• Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res.64(24), 9209–9216 (2004).
   PubMed Web of Science ®Google Scholar
• Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer101(5), 894–904 (2004).
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med.317(15), 909–916 (1987).
   PubMed Web of Science ®Google Scholar
• Swallow T, Kirby RS. Cancer of the prostate gland. Surgery (Oxford)24(5), 173–176 (2006).
   Google Scholar
• Charrier JP, Tournel C, Michel S et al. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis22(9), 1861–1816 (2001).
   PubMed Web of Science ®Google Scholar
• Gao X, Porter AT, Grignon DJ, Edson Pontes J, Honn KV. Diagnostic and prognostic markers for human prostate cancer. Prostate31(4), 264–281 (1997).
   PubMed Web of Science ®Google Scholar
• Yu H, Berkel H. Prostate-specific antigen (PSA) in women. J. La State Med. Soc.151(4), 209 (1999).
   PubMedGoogle Scholar
• Pryor MB, Schellhammer PF. The pursuit of prostate cancer in patients with a rising prostate-specific antigen and multiple negative transrectal ultrasound-guided prostate biopsies. Clin. Genitourin. Cancer1(3), 172–176 (2002).
   Google Scholar
• Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N. Engl. J. Med.350(22), 2239–2246 (2004).
   PubMed Web of Science ®Google Scholar
• Troyer DA, Mubiru J, Leach RJ, Naylor SL. Promise and challenge: markers of prostate cancer detection, diagnosis and prognosis. Dis. Markers20(2), 117–128 (2004).
   PubMedGoogle Scholar
• Leibovici D, Spiess PE, Agarwal PK et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer109(2), 198–204 (2007).
   PubMedGoogle Scholar
• de Kok JB, Verhaegh GW, Roelofs RW et al. DD3 PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res.62(9), 2695–2698 (2002).
   PubMed Web of Science ®Google Scholar
• Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3(DD3 PCa3), a highly prostate cancer-specific gene. Urology62(A5), 34–43 (2003).
   PubMedGoogle Scholar
• Hessels D, Klein Gunnewiek JMT, van Oort I et al.DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol.44(1), 8–16 (2003).
   PubMed Web of Science ®Google Scholar
• Deras IL, Aubin SMJ, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol.179(4), 1587–1592 (2008).
   PubMed Web of Science ®Google Scholar
• Amin MB, Grignon D, Humphrey P, Srigley J. Gleason Grading of Prostate Cancer: a Contemporary Approach. Lippincott Williams & Wilkins, PA, USA (2003).
   Google Scholar
• Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA293(17), 2095–2101 (2005).
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA280(11), 975–980 (1998).
   PubMed Web of Science ®Google Scholar
• Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer112(5), 971–981 (2008).
   PubMedGoogle Scholar
• Shariat S, Karam J, Margulis V, Karakiewicz P. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int.101(6), 675–683 (2008).
   PubMed Web of Science ®Google Scholar
• Rhodes D, Sanda M, Otte A, Chinnaiyan A, Rubin M. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl Cancer Inst.95(9), 661–668 (2003).
   PubMed Web of Science ®Google Scholar
• Lexander H, Palmberg C, Hellman U et al. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics6(15), 4370–4380 (2006).
   PubMed Web of Science ®Google Scholar
• Lee WH, Morton RA, Epstein JI et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA91(24), 11733–11737 (1994).
   PubMed Web of Science ®Google Scholar
• Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res.8(2), 514–519 (2002).
   PubMed Web of Science ®Google Scholar
• Johansson B, Pourian MR, Chuan YC et al. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy. Prostate66(12), 1235–1244 (2006).
   PubMedGoogle Scholar
• Horoszewicz JS, Leong SS, Kawinski E et al. LNCaP model of human prostatic carcinoma. Cancer Res43(4), 1809–1818 (1983).
   PubMed Web of Science ®Google Scholar
• Dozmorov MG, Hurst RE, Culkin DJ et al. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate69(10), 1077–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Corey E, Quinn JE, Buhler KR et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate55(4), 239–246 (2003).
   PubMed Web of Science ®Google Scholar
• Qingyi Z, Lin Y, Junhong W et al. Unfavorable prognostic value of human pedf decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach. Cancer Invest.27(7), 794–801 (2009).
   PubMed Web of Science ®Google Scholar
• Byrne JC, Downes MR, O’Donoghue N et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J. Proteome Res.8(2), 942–957 (2009).
   PubMedGoogle Scholar
• Rowland JG, Robson JL, Simon WJ, Leung HY, Slabas AR. Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics7(1), 47–63 (2007).
   PubMedGoogle Scholar
• Qin S, Ferdinand AS, Richie JP, O’Leary MP, Mok SC, Liu BCS. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics5(12), 3183–3192 (2005).
   PubMedGoogle Scholar
• Griffin TJ, Han DKM, Gygi SP et al. Toward a high-throughput approach to quantitative proteomic analysis: expression-dependent protein identification by mass spectrometry. J. Am. Soc. Mass Spectrom.12(12), 1238–1246 (2001).
   PubMed Web of Science ®Google Scholar
• Arnott D, Kishiyama A, Luis EA, Ludlum SG, Marsters JC, Stults JT. Selective detection of membrane proteins without antibodies a mass spectrometric version of the western blot. Mol. Cell Proteomics1(2), 148–156 (2002).
   PubMed Web of Science ®Google Scholar
• Wright ME, Eng J, Sherman J et al. Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol.5(1), 4 (2004).
   Google Scholar
• Meehan KL, Sadar MD. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics4(4), 1116–1134 (2004).
   PubMedGoogle Scholar
• Martin DB, Gifford DR, Wright ME et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res.64(1), 347–355 (2004)
   PubMed Web of Science ®Google Scholar
• Garbis SD, Tyritzis SI, Roumeliotis T et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res.7(8), 3146–3158 (2008).
   PubMed Web of Science ®Google Scholar
• Glen A, Gan CS, Hamdy FC et al. iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J. Proteome Res.7(3), 897–907 (2008).
   PubMed Web of Science ®Google Scholar
• Pettaway CA, Pathak S, Greene G et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res.2(9), 1627–1636 (1996).
   PubMed Web of Science ®Google Scholar
• Nagano K, Masters JR, Akpan A et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene23(9), 1693–1703 (2003).
   Google Scholar
• Sardana G, Jung K, Stephan C, Diamandis EP. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res.7(8), 3329–3338 (2008).
   PubMed Web of Science ®Google Scholar
• Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res.62(13), 3609–3614 (2002).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst.94(20), 1576–1578 (2002).
   PubMed Web of Science ®Google Scholar
• Qu Y, Adam BL, Yasui Y et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem.48(10), 1835–1843 (2002).
   PubMed Web of Science ®Google Scholar
• Pan YZ, Xiao XY, Zhao D et al. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer. Asian J. Androl.8(1), 45–51 (2006).
   PubMedGoogle Scholar
• Malik G, Ward MD, Gupta SK et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res.11(3), 1073–1085 (2005).
   PubMed Web of Science ®Google Scholar
• Ehmann M, Felix K, Hartmann D et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas34(2), 205–214 (2007).
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer4(4), 309–314 (2004).
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem.54(1), 44–52 (2008).
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem.54(1), 53–60 (2008).
   PubMed Web of Science ®Google Scholar
• Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics1(10), 1264–1270 (2001).
   PubMed Web of Science ®Google Scholar
• Alper J. Glycobiology. Turning sweet on cancer. Science301(5630), 159–160 (2003).
   PubMedGoogle Scholar
• Downes MR, Byrne JC, Dunn MJ, Fitzpatrick JM, Watson RW, Pennington SR. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers11(5), 406–416 (2006).
   PubMed Web of Science ®Google Scholar
• Ornstein DK, Tyson DR. Proteomics for the identification of new prostate cancer biomarkers. Urol. Oncol.24(3), 231–236 (2006).
   PubMedGoogle Scholar
• Tabares G, Radcliffe CM, Barrabes S et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology16(2), 132–145 (2006).
   PubMedGoogle Scholar
• Kyselova Z, Mechref Y, Al Bataineh MM et al. Alterations in the serum glycome due to metastatic prostate cancer. J. Proteome Res.6(5), 1822–1832 (2007).
   PubMed Web of Science ®Google Scholar
• Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J. Proteome Res.8(2), 613–619 (2009).
   PubMedGoogle Scholar
• Grubb RL, Deng J, Pinto PA et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J. Proteome Res.8(6), 3044–3054 (2009).
   PubMed Web of Science ®Google Scholar
• Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol.1(1), 18–28 (1995).
   PubMedGoogle Scholar
• Beckett ML, Cazares LH, Vlahou A, Schellhammer PF, Wright GL. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer 1. Cancer Res.5(12), 4034–4040 (1999).
   Google Scholar
• Xiao Z, Adam BL, Cazares LH et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res.61(16), 6029–6033 (2001).
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science310(5748), 644–648 (2005).
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature457(7231), 910–914 (2009).
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer5(2), 142–149 (2005).
   PubMed Web of Science ®Google Scholar
• Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med.149(3), 192–199 (2008).
   PubMed Web of Science ®Google Scholar
• Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl Cancer Inst.95(12), 868–878 (2003).
   PubMed Web of Science ®Google Scholar
• Drake RR, White KY, Fuller TW et al. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J. Proteomics72(6), 907–917 (2009).
   PubMed Web of Science ®Google Scholar
• Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res.8(3), 1489–1503 (2009).
   PubMed Web of Science ®Google Scholar
• Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun.292(3), 587–592 (2002).
   PubMed Web of Science ®Google Scholar